Research identifies promising biomarker for early sepsis detection in neonates, kids and pregnant ladies

A examine introduced at ESCMID World 2025 has uncovered the potential of interleukin-6 (IL-6) as a robust diagnostic biomarker for the early detection of sepsis in high-risk affected person teams, together with neonates, kids and pregnant ladies. This examine is the primary to judge IL-6’s diagnostic efficiency in a real-world cohort throughout all three populations.

Sepsis, a life-threatening situation ensuing from the immune system’s overreaction to an infection, stays a number one world reason behind mortality, accounting for an estimated 11 million deaths yearly.

Younger kids, particularly these beneath 5, and pregnant ladies are extremely weak attributable to immunological modifications and elevated susceptibility. Diagnosing sepsis throughout being pregnant is particularly difficult, as physiological modifications can obscure its early indicators.

Immediate prognosis is crucial, but difficult, as a result of non-specific signs of sepsis and the restrictions of conventional diagnostic biomarkers, resembling C-reactive protein (CRP) and procalcitonin (PCT), which have delayed responses and suboptimal sensitivity. Given the speedy development of sepsis, there’s an pressing want for biomarkers that provide sooner, extra correct prognosis to allow well timed intervention.

The retrospective cohort examine analyzed serial blood samples from 252 sufferers (111 pediatric, 72 maternity, and 69 neonatal instances) with suspected sepsis.

Sufferers have been labeled by an infection kind (bacterial, viral, or no an infection) and physiological response (regular, systemic inflammatory response syndrome, sepsis and septic shock). Diagnostic accuracy was evaluated via AUROC evaluation (starting from 1.0, an ideal take a look at with 100% specificity and sensitivity, to 0.5, a very ineffective take a look at).

IL-6 persistently outperformed conventional biomarkers in distinguishing bacterial from non-bacterial infections, with AUROC values of 0.91 in kids, 0.94 in maternal sufferers, and 0.86 in neonates. IL-6 additionally successfully stratified sepsis severity, distinguishing between gentle an infection, sepsis, and septic shock, a crucial functionality for guiding well timed and applicable remedy.

By way of sensitivity and specificity, IL-6 exceeded 80% in each pediatric and maternal sufferers, detecting bacterial infections with 91% sensitivity in kids and 94% in pregnant ladies. In neonates, whereas IL-6 maintained excessive specificity (97.1%), its sensitivity (67.6%) was decrease.

These decrease sensitivity and AUROC values could also be partly attributable to the complexities of diagnosing neonatal sepsis, the place there isn’t a clear consensus definition. The broader spectrum of displays in neonatal sepsis may additionally contribute to those variations.

Discussing the benefits of IL-6 over conventional biomarkers, Dr. Seán Whelan, lead writer, explains, “IL-6 secretion rises inside one to 2 hours, peaks at six hours and reduces by 24 hours, whereas CRP and PCT peak a lot later at 48 and 24 hours, respectively. This sooner, steeper response makes IL-6 a promising biomarker for earlier sepsis detection.”

Dr. Whelan additionally highlighted its rising scientific utility. “IL-6 is already in routine use in our establishments, the Rotunda Hospital and Kids’s Well being Eire at Temple Road, for these populations.

“The challenges to wider adoption have been lessened by the event of commercially out there testing on generally used platforms, which may present real-time outcomes. The COVID-19 pandemic accelerated this course of, as IL-6 testing grew to become extra broadly utilized in assessing affected person irritation.”

“Our findings reinforce the potential of IL-6 as a promising biomarker in sepsis prognosis”, concludes Dr. Whelan. “With wider adoption and together with scientific evaluation, IL-6 might considerably enhance scientific decision-making and help well timed, focused remedy for high-risk sufferers.”

Offered by
European Society of Medical Microbiology and Infectious Ailments